Atrial Fibrillation and Decompensated Heart Failure

Kim, Sung-Hwan, MD.

Seoul St. Mary's Hospital

The Catholic University of Korea





AF is increasing





Problems of AF (with HF)

- Decreased pump function
 - loss of atrial contraction, AV dyssynchrony, tachycardia induced cardiomyopathy

- **Stroke**, side effects of anticoagulation
- Symptom; palpitation, dyspnea, general weakness
- hospitalization



AF -> more severe stroke !

Stroke	All Ages		
Severity	AF (n=103)	Non-AF (n=398)	
None	21%	19%	
Mild	21%	26%	
Moderate	17%	26%	
Severe	14%	14%	
Fatal	25%	14%	
P⁺	.048		

The Framingham study, Lin et al, Stroke 1996



Treatment strategies of AF

- aspirin vs. warfarin (NOAC)

- rate vs. rhythm





Strategy (1) – antithrombotic

- As CHA₂DS₂–VASc score, in non-valvular AF
 - Congestive heart failure (1)
 - Hypertension (1)
 - **A**ge (>75) (2)
 - Diabetes (1)
 - Stroke (2)
 - Vascular disease
 - Age (65~74) (1)
 - Sex (female) (1)
- 0 : no or aspirin, 1 : aspirin or warfarin, ≥ 2 : warfarin





Non-valvular AF ?

- Mitral stenosis, mechanical valve, HCMP
 - \Rightarrow High risk of thrombus
 - \Rightarrow Absolute indication of warfarin
- Non-valvular AF
 - The other
 - ex.) severe MR, severe AR...





Strategy (2) – Rate vs. Rhythm

- Rate control drug
 - Beta blocker (bisoprolol, carvedilol, esmolol...), digoxin, CCB (diltiazem, verapamil)
- Antiarrhythmic drug
 - Ic drug (flecainide, propafenone)
 - III drug (amiodarone)
- RFCA (radiofrequency catheter ablation)
- MAZE, thoracoscopic



A COMPARISON OF RATE CONTROL AND RHYTHM CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION

THE ATRIAL FIBRILLATION FOLLOW-UP INVESTIGATION OF RHYTHM MANAGEMENT (AFFIRM) INVESTIGATORS*



Figure 2. Ischemic stroke over time. The values are given as the number of patients, the number of events, and the percentage of events for the given period in the accompanying chart.





NEJM 2002

rhythm control 군 중 40% 가 rate control 군으로 cross over !

Arch Intern Med. 2005

Figure 3. All strokes over time. The values are given as the number of patients, the number of events, and the percentage of events for the given period in the accompanying chart.

JL OF MEDICINE



On-treatment analysis of AFFIRM - stroke

Covariate	<i>P</i> Value	HR (95% CL)	Increase or Decrease in Risk, %
Age	.02	1.02 (1.00, 1.04)	+2 (per year of age)
Female sex	.003	1.66 (1.19, 2.31)	+66
Duration of qualifying episode $\geq 2 d$.02	1.61 (1.08, 2.40)	+61
Stroke or TIA	.006	1.78 (1.19, 2.68)	+78
Diabetes mellitus	.01	1.62 (1.11, 2.35)	+62
AF	.01	1.60 (1.11, 2.30)	+60
Warfarin sodium therapy	<.001	0.31 (0.21, 0.46)	-69

Arch Intern Med. 2005





On-treatment analysis of AFFIRM - death

			HR: 99% Confidence Limits	
Covariate	Р	HR	Lower	Upper
Age at enrollment*	< 0.0001	1.06	1.04	1.08
Coronary artery disease	< 0.0001	1.65	1.31	2.07
Sinus rhythm	< 0.0001	0.54	0.42	0.70
Warfarin use	< 0.0001	0.47	0.36	0.61
Digoxin use	< 0.0001	1.50	1.18	1.89
Rhythm-control drug use	0.0005	1.41	1.10	1.83

Consistent with the original intention-to-treat analysis,

Anti-arrhythmic drug were no longer associated with mortality when SR was removed from the model. Arch Intern Med. 2005

THE CATHOLIC UNIVERSITY OF KOREA, SCHOOL OF MEDICINE



Messages from AFFIRM trial

 Sinus 로 유지만 된다면, rhythm control strategy 가 stroke 예방에 확실히 좋다.

- 잘 유지될 것 같은 환자들을 골라서 rhythm control 하자

Sinus 로 유지된다고 한들, mortality 는 차이 없다.
- 항부정맥제는 역시 위험한 약이다.





AF begets AF by atrial remodeling







Mechanism of AF

Paroxysmal AF -----> Permanent AF







Rhythm control favor

- Probability of sinus maintenance
 - Paroxysmal, not long-standing, LA < 45~50 mm
- Young
- Severe symptom
- AF complication (= stroke)





Classification of AF

	Paroxysmal	Persistent	Long- standing persistent	permanent
Definition (duration)	Spontaneous termination	> 7d	> 12m	Acceptance of AF rhythm
Possibility of Rhythm control	+++	++	+	-





Ablation vs. Antiarrhythmic drug



Ablation Versus Antiarrhythmic Therapy: Randomized Trials



THE CATHOLIC UNIVERSITY OF KOREA, SCHOOL OF MEDICINE

Ablation vs. Amiodarone for AF + CHF

- Target (n=203): pe AF, $EF \le 40\%$ (Fc II, III), with ICD
- Primary endpoint: AF free survival (2 yr)
- Secondary endpoints: mortality, QoL, EF change...



AATAC trial, Late breaking in ACC 15.





Ablation vs. Amiodarone for AF + CHF

- LVEF improved 9.67.4%, vs. 4.26.2% (p<0.001)
- 6MWD changed 2738 vs. 842 (p<0.001)
- MLHFQ score reduced 14 vs. 2.9 (p<0.001) in recurrence versus not
- Hospitalization rate substantially lower in ablation (31% vs. 57%, p <0.001)
- All-cause mortality lower in ablation (8% vs. 18%, p=0.037)

AATAC trial, Late breaking in ACC 15.





The risk of RFCA for AF

Type of Complication	No. of Patients	Rate, %
Death	25	0.15
Tamponade	213	1.31
Pneumothorax	15	0.09
Hemothorax	4	0.02
Sepsis, abscesses, or endocarditis	2	0.01
Permanent diaphragmatic paralysis	28	0.17
Total femoral pseudoaneurysm	152	0.93
Total artero-venous fistulae	88	0.54
Valve damage/requiring surgery	11/7	0.07
Atrium-esophageal fistulae	6	0.04
Stroke	37	0.23
Transient ischemic attack	115	0.71
PV stenoses requiring intervention	48	0.29
Total	741	4.54

Cappato et al. Burkhardt al. Circ Arrhythm Electrophysiol. 2010



Significance of Typical Atrial Flutter





Macroreentry circuit of typical AFL







Typical AFL, carvotricuspid isthmus-dependent AFL (counterclock wise rotation)







AF & (Typical) AFL

	AF	(Typical) AFL	
Similar	Stroke risk, decreasing cardiac output, commonly combined		
Mechanism	Automaticity/microreentr y	Macroreentry	
Regularity	Irregularly irregular	Sometimes, regular	
Rate control	Relatively easy	Difficult (more symptomatic)	
Recurrence after one ablation	30~50%	< 5% (unmasked AF 30%)	
Procedure time	3~4 hr	< 1 hr	
LA approach/3D ma pping	+	-	





Take hospital messages

- Heart has two pumps! atrium as well as ventricle.
- If it will be possible, rhythm control recover atrium and make better outcomes.
- Typical AFL is a good candidate for catheter ablation.

